SCHEMBL1663885

SCHEMBL1663885

CC(C)c1nc2cc(O)ccc2c(=O)n1Cc1ccccc1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5AP P20292 7/20 0.52
TRPV1 Q8NER1 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.45
ALDH1A1 P00352 4/20 0.44
MAPT P10636 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
CYP1A2 P05177 2/20 0.43
CYP3A4 P08684 2/20 0.43
CYP2C9 P11712 2/20 0.43
CYP2C19 P33261 2/20 0.43
USP2 O75604 1/20 0.43
HSD17B10 Q99714 1/20 0.43
HDAC1 Q13547 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
LMNA P02545 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
TSHR P16473 2/20 0.41
PTGES O14684 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1663099 0.87 TRPV1 (0.47) ALOX5APTRPV1ALDH1A1MAPTSMN1; SMN2
SCHEMBL1663625 0.81 TRPV1 (0.50) ALOX5APTRPV1ALDH1A1MAPTMEN1
SCHEMBL1666102 0.79 TRPV1 (0.43) ALOX5APTRPV1ALDH1A1HDAC1HDAC6
SCHEMBL20061290 0.78 ALOX5AP (0.49) ALOX5APALDH1A1MAPTMEN1KMT2A
SCHEMBL1663990 0.78 TRPV1 (0.47) TRPV1MAPTMEN1KMT2AHDAC1
SCHEMBL1663843 0.78 AKR1B1 (0.48) TRPV1L3MBTL1ALDH1A1MAPTSMN1; SMN2
SCHEMBL1663421 0.77 TRPV1 (0.54) TRPV1ALDH1A1SMN1; SMN2CYP1A2CYP2C9
SCHEMBL1664148 0.77 TRPV1 (0.54) TRPV1ALDH1A1MAPTMEN1KMT2A
SCHEMBL1663833 0.77 TRPV1 (0.47) ALOX5APTRPV1L3MBTL1ALDH1A1MAPT
SCHEMBL1663509 0.76 TRPV1 (0.48) TRPV1ALDH1A1MAPTSMN1; SMN2HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2305652-A2 Trisubstituted quinazolinone derivatives as vanilloid antagonists Novartis AG (CH) 2011-04-06 EP disclosed
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists NOVARTIS AG 2009-03-26 US disclosed
CN-101356160-A Trisubstituted quinazolinone derivatives as vanilloid antagonists JANSSEN PHARMACEUTICA NV (CH) 2009-01-28 CN disclosed
EP-1963283-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS Novartis AG (CH) 2008-09-03 EP disclosed
WO-2007065662-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS NOVARTIS AG (CH) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists TRPV1, TRPV3, TRPV5 ALOX5AP 1829/4885TRPV1 1/4885L3MBTL1 3372/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.